Intercept Pharmaceuticals Inc.

67.05+4.14+6.58%Vol 408.54K1Y Perf -44.23%
Apr 8th, 2020 16:00
BID67.04 ASK67.44
Open64.88 Previous Close62.91
Pre-Market- After-Market67.05
 - -%  - -%
Target Price
151.56 
Analyst Rating
Strong Buy 1.40
Potential %
126.04 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-68 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-26 
Growth Ranking
★+     41.60
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-7 
Income Ranking
 —    -
Market Cap2.20B 
Earnings Rating
Sell
Price Range Ratio 52W %
25.16 
Earnings Date
13th May 2020

Today's Price Range

63.5367.67

52W Range

47.57125.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
11.42%
1 Month
-20.68%
3 Months
-42.96%
6 Months
16.89%
1 Year
-44.23%
3 Years
-38.32%
5 Years
-75.33%
10 Years
-

TickerPriceChg.Chg.%
ICPT67.054.14006.58
AAPL266.076.64002.56
GOOG1 210.2823.77002.00
MSFT165.131.64001.00
XOM43.852.61006.33
WFC30.281.51005.25
JNJ143.265.78004.20
FB174.285.45003.23
GE7.300.27003.84
JPM94.303.66004.04
Earnings HistoryEstimateReportedSurprise %
Q04 2019-2.56-2.99-16.80
Q03 2019-2.35-2.59-10.21
Q02 2019-2.51-2.289.16
Q01 2019-2.57-3.03-17.90
Q04 2018-2.42-2.97-22.73
Q03 2018-2.65-2.1817.74
Q02 2018-2.83-2.588.83
Q01 2018-3.41-3.225.57
Earnings Per EndEstimateRevision %Trend
3/2020 QR-2.83-6.79Negative
6/2020 QR-2.83-14.57Negative
12/2020 FY-11.01-6.89Negative
12/2021 FY-8.24-415.00Negative
Next Report Date13th May 2020
Estimated EPS Next Report-2.83
Estimates Count11
EPS Growth Next 5 Years %-
Volume Overview
Volume408.54K
Shares Outstanding32.85M
Trades Count7.70K
Dollar Volume31.63M
Avg. Volume592.63K
Avg. Weekly Volume494.53K
Avg. Monthly Volume665.70K
Avg. Quarterly Volume589.55K

Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) closed at 67.05 per share at the end of the most recent trading day (a 6.58% change compared to the prior day closing price) with a volume of 463.42K shares and market capitalization of 2.20B. Is a component of indexes and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 483 people. Intercept Pharmaceuticals Inc. CEO is Mark Pruzanski.

The one-year performance of Intercept Pharmaceuticals Inc. stock is -44.23%, while year-to-date (YTD) performance is -45.89%. ICPT stock has a five-year performance of -75.33%. Its 52-week range is between 47.57 and 125, which gives ICPT stock a 52-week price range ratio of 25.16%

Intercept Pharmaceuticals Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 37.44, a price-to-sale (PS) ratio of 10.34, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -55.06%, a ROC of -61.51% and a ROE of -981.52%. The company’s profit margin is -%, its EBITDA margin is -119.00%, and its revenue ttm is $199.75 Million , which makes it $6.08 revenue per share.

Of the last four earnings reports from Intercept Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.83 for the next earnings report. Intercept Pharmaceuticals Inc.’s next earnings report date is 13th May 2020.

The consensus rating of Wall Street analysts for Intercept Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $151.56, which is +126.04% compared to the current price. The earnings rating for Intercept Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Intercept Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Intercept Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 33.99, ATR14 : 6.19, CCI20 : 83.04, Chaikin Money Flow : -0.06, MACD : -4.70, Money Flow Index : 66.81, ROC : 15.52, RSI : 48.63, STOCH (14,3) : 79.04, STOCH RSI : 1.00, UO : 48.28, Williams %R : -20.96), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Intercept Pharmaceuticals Inc. in the last 12-months were: Christian Weyer (Sold 0 shares of value $-395 885 ), Christian Weyer (Sold 11 028 shares of value $1 097 793 ), David A. Ford (Sold 858 shares of value $60 060 ), David Shapiro (Sold 0 shares of value $-255 200 ), David Shapiro (Sold 8 000 shares of value $725 120 ), Gail Cawkwell (Sold 0 shares of value $-117 236 ), Gail Cawkwell (Sold 316 shares of value $39 500 ), Jason Campagna (Sold 886 shares of value $101 126 ), Lisa Bright (Sold 1 785 shares of value $138 230 ), Luca Benatti (Buy at a value of $100 200), Mark Pruzanski (Sold 0 shares of value $-644 098 ), Mark Pruzanski (Sold 50 517 shares of value $5 064 625 ), Paolo Fundaro (Sold 0 shares of value $-102 887 ), Ryan T. Sullivan (Sold 0 shares of value $-471 343 ), Ryan T. Sullivan (Sold 12 654 shares of value $1 075 590 ), Srinivas Akkaraju (Buy at a value of $4 812 663), Srinivas Akkaraju (Sold 0 shares of value $-85 660 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (80.00 %)
12 (85.71 %)
13 (72.22 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
2 (11.11 %)
Hold
3 (20.00 %)
2 (14.29 %)
2 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (5.56 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.29
Moderate Buy
1.56

Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

CEO: Mark Pruzanski

Teplephone: +1 646 747-1000

Address: 10 Hudson Yards, New York 10011, NY, USA

Number of employees: 483

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

31%69%

Bearish Bullish

70%30%

News

Stocktwits